Achilles Therapeutics
London
United Kingdom
About Achilles Therapeutics
Achilles intends to develop next-generation personalized vaccines and adoptive T cell therapies for metastatic cancer by targeting truncal tumor neoantigens. The company is based on research at University College London, Cancer Research UK (CRUK) and the Francis Crick Institute.YEAR FOUNDED:
2016
LEADERSHIP:
Scientific Founder: Charles Swanton
CEO: Chris Ashton
59 articles with Achilles Therapeutics
-
Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
3/7/2023
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2022, and recent business highlights.
-
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/20/2022
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 am PST.
-
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
12/6/2022
Achilles Therapeutics plc today presented an encouraging interim Phase I/IIa update on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma at the ESMO Immuno-Oncology Congress 2022 (ESMO IO).
-
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
11/30/2022
Achilles Therapeutics plc (NASDAQ: ACHL) today announced that an abstract highlighting updated interim results from the ongoing Phase I/IIa CHIRON and THETIS clinical trials evaluating clonal neoantigen-reactive T cells (cNeT) has been accepted for a poster presentation at the ESMO Immuno-Oncology Annual Congress (ESMO IO) taking place in Geneva, Switzerland from December 7-9, 2022.
-
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
11/22/2022
Achilles Therapeutics plc today announced that United States (US) patent 11,504,398 has been granted.
-
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
11/8/2022
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced its financial results for the third quarter ended September 30, 2022, and recent business highlights.
-
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
10/6/2022
Achilles Therapeutics plc today announced that its Co-founder Charles Swanton, MD, PhD, FRS, FRCP from the Francis Crick Institute & UCL, and Scientific Advisory Board member Christopher Klebanoff from Memorial Sloan Kettering will join John Haanen, MD from the Netherlands Cancer Institute on a Neoantigen Expert Roundtable to discuss the importance of neoantigens as targets in solid tumor cell therapy.
-
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
7/21/2022
Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced that it is leading a consortium that has been awarded a €4 million grant from Horizon Europe, the European Union’s key funding program for research and innovation.
-
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board
6/30/2022
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022.
-
Achilles Therapeutics Recognized with the 2022 PING Innovation Award
6/21/2022
Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced that the Company was named the winner of the Pharmaceutical Industry Network Group Innovation Award.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Researchers at Yale University published research in Molecular Biology and Evolution describing a new molecular analysis approach to quantify DNA changes that contribute to cancer growth.
-
Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
5/10/2022
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2022, and recent business highlights.
-
Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma
5/9/2022
Achilles Therapeutics plc (NASDAQ: ACHL), today announced that the first patient has been dosed with personalized clonal neoantigen-reactive T cells, or cNeT, manufactured with the Company’s higher-dose VELOS™ Process 2 in the ongoing Phase I/IIa CHIRON clinical trial for the treatment of advanced non-small cell lung cancer (NSCLC).
-
BioSpace Movers & Shakers, May 6
5/6/2022
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors
5/4/2022
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Board as a Non-Executive Director.
-
Achilles Therapeutics to Present at Upcoming Conferences
5/3/2022
Achilles Therapeutics plc today announced that the Company will be taking part in the following conferences in May.
-
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
-
Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US
4/12/2022
Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced clinical manufacturing expansion in the United Kingdom and the United States.
-
Achilles Therapeutics to Present at Upcoming Conferences - Apr 05, 2022
4/5/2022
Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced that management will be taking part in the following conferences in April.